Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.
about
Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legsCryo-electron tomographic structure of an immunodeficiency virus envelope complex in situHuman immunodeficiency virus type 1 gp120 and other activation stimuli are highly effective in triggering alpha interferon and CC chemokine production in circulating plasmacytoid but not myeloid dendritic cells.HIV type 1 Gag as a target for antiviral therapyHyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionApplication of radiation technology in vaccines developmentMolecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structureA tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessationSlow turnover of HIV-1 receptors on quiescent CD4+ T cells causes prolonged surface retention of gp120 immune complexes in vivoAttenuation of pathogenic immune responses during infection with human and simian immunodeficiency virus (HIV/SIV) by the tetracycline derivative minocyclineAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesMolecular architecture of native HIV-1 gp120 trimersDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingTopology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranesTargeting of arenavirus RNA synthesis by a carboxamide-derivatized aromatic disulfide with virucidal activityα1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 diseaseN(6)-methyladenosine of HIV-1 RNA regulates viral infection and HIV-1 Gag protein expressionHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesAggregate complexes of HIV-1 induced by multimeric antibodies.DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion.Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography.Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activationIn vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection.Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.Inactivation of respiratory syncytial virus by zinc finger reactive compounds.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesElimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteinsInduction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitutionCD4(+) T-lymphocyte depletion in human lymphoid tissue ex vivo is not induced by noninfectious human immunodeficiency virus type 1 virions.Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatmentEnhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost
P2860
Q21090520-8061600C-6533-4AA9-96FD-3D6BF3CA420DQ21090535-40CCE010-E1EA-44E7-9C25-EC4E04FA2571Q24533328-CEC81888-EFDE-4357-A965-F63C93279FCFQ24614498-0A4A906E-4C52-4599-8962-2201C9FDF95CQ24679395-71F9BBE7-28E3-4B2C-8300-49FC308AD0ECQ26775082-B024A9A1-0D00-49A1-95C4-0C1C4719BE9FQ26798165-9A524064-77E5-434F-A68E-84DF13AAD901Q27312441-E365ABAF-C842-450C-B7B1-02EDC164C7DAQ27319650-60676BD3-9348-48EE-ABFC-EEC395609E91Q27330487-D75B042E-32A8-4CD2-9EAC-9A1979E908C1Q27342233-03F78E10-ED89-4EB4-8A99-F32C232D37BEQ27489000-6E219E3C-9EE2-4341-98D7-5D650FFCCD11Q27651385-70A3491C-FA8A-43BA-96F2-EBCA1BC6E49FQ27675486-929F0EE6-B81F-4B19-8F35-BE4D958D3407Q28476449-37389E74-EDD8-4ED0-8D8A-42F064F0F189Q28535297-2230E243-C553-4FB6-AE5E-EAEFED6A9C7EQ28731975-73B0AD18-42EE-4BF0-87C5-1B79569D491FQ28828855-18997F90-1AC3-40F7-AAB0-5FB193B78A22Q29619015-631E1CE7-D95D-4FC5-9270-1D862DF89C6BQ30428633-E3F10F31-EB07-415E-9B9A-3BC303CB3B08Q30472149-ADDF30CD-47D1-4EF8-A58F-275573DCD0A4Q30499561-8BC265F4-3977-425D-852B-45FBE67D7879Q30507959-1591AA4E-AF4E-4152-A855-7405F2E97009Q30603475-FDC5862B-7557-4ED0-B836-76B7FAE5A96DQ30621111-8C210D37-326D-4CE4-83D7-A3CF1B64E910Q31106756-7EFAB056-8732-49FC-B03C-B62F7D7BAF53Q33315307-1FEBA593-A2A3-4C7B-8EC2-918AA92818CAQ33359564-D95A6B42-FB26-4DE8-9BF4-C626735E44D2Q33402486-D950C5EC-E7D8-4CEC-8E32-DE22F786BB0EQ33648180-15541794-C21D-4062-BD73-FA557E96A359Q33663190-26A1BF97-96FF-438B-B496-A2976B7C0087Q33683203-EA108055-B898-468D-BE1C-6DF03B05C91AQ33718048-E95484F6-9C41-46B7-9B2D-424111F5241FQ33724169-764285FD-DC0B-4374-B66D-2AE1B2BEB4CDQ33778466-BA932362-63B6-40A5-9EF6-6B3294B7F2E8Q33785495-5875CC1F-D2B1-473F-8925-CA0C7FD8F637Q33787256-2ACF6D51-0301-40DB-A9C2-6C3F62791BC3Q33799700-48F00E7F-754D-4B37-BD03-A55527649BFBQ33806303-D1E0D4C6-870C-4EE8-8940-A8691A2A03B6Q33813173-F5193EB5-E3FC-4B8B-82B9-4783FF6A8BAE
P2860
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Inactivation of human immunode ...... ty of virion surface proteins.
@ast
Inactivation of human immunode ...... ty of virion surface proteins.
@en
type
label
Inactivation of human immunode ...... ty of virion surface proteins.
@ast
Inactivation of human immunode ...... ty of virion surface proteins.
@en
prefLabel
Inactivation of human immunode ...... ty of virion surface proteins.
@ast
Inactivation of human immunode ...... ty of virion surface proteins.
@en
P2093
P2860
P1433
P1476
Inactivation of human immunode ...... ity of virion surface proteins
@en
P2093
D K Schneider
E Chertova
G M Vasquez
J D Lifson
J L Rossio
K Suryanarayana
L E Henderson
L O Arthur
M K Grimes
P2860
P304
P577
1998-10-01T00:00:00Z